OncoCyte Corporation (OCX) Social Stream
ONCOCYTE CORP (OCX) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering OCX.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 3 | $11 | $5 | $7.75 | $0.214 | 3521.5% |
| 2021-11-10 | 3 | $11 | $7 | $8.333 | $0.214 | 3793.93% |
| 2021-12-16 | 3 | $11 | $5 | $7.666 | $0.214 | 3482.24% |
| 2022-01-06 | 5 | $11 | $3.1 | $6.525 | $0.214 | 2949.07% |
| 2022-02-01 | 5 | $11 | $3.1 | $5.84 | $0.214 | 2628.97% |
| 2022-03-17 | 5 | $11 | $1.8 | $5.225 | $0.214 | 2341.59% |
| 2022-04-01 | 5 | $11 | $1.8 | $4.95 | $0.214 | 2213.08% |
| 2022-05-16 | 5 | $11 | $1.4 | $4.85 | $0.214 | 2166.36% |
| 2022-06-06 | 5 | $11 | $1.25 | $4.662 | $0.214 | 2078.5% |
| 2022-08-11 | 6 | $4 | $1.25 | $2.35 | $0.214 | 998.13% |
| 2022-08-17 | 6 | $4 | $1.25 | $2.37 | $0.214 | 1007.48% |
| 2022-09-01 | 6 | $4 | $1.15 | $2.35 | $0.214 | 998.13% |
| 2022-11-01 | 5 | $4 | $0.9 | $2.3 | $0.214 | 974.77% |
| 2022-11-11 | 5 | $4 | $0.9 | $2.16 | $0.214 | 909.35% |
| 2022-11-14 | 5 | $4 | $0.9 | $2.06 | $0.214 | 862.62% |
| 2022-11-18 | 5 | $4 | $0.5 | $1.96 | $0.214 | 815.89% |
| 2022-12-07 | 5 | $4 | $0.5 | $1.46 | $0.214 | 582.24% |
| 2023-04-10 | 5 | $4 | $0.4 | $1.36 | $0.214 | 535.51% |
| 2023-05-01 | 4 | $4 | $0.4 | $1.17 | $0.214 | 446.73% |
| 2023-05-14 | 3 | $4 | $0.3 | $1.287 | $0.214 | 501.4% |
The Trend in the Analyst Price Target
OCX's average price target has moved down $6.38 over the prior 17 months.
Over the past 49 weeks, OCX's average upside potential has been 276.68%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-08-17 | 6 | 4 | 1.25 | 2.370 | 0.874 | 171.17% |
| 2022-11-18 | 5 | 4 | 0.50 | 1.960 | 0.440 | 345.45% |
| 2023-02-02 | 5 | 4 | 0.40 | 1.360 | 0.388 | 250.52% |
| 2023-04-10 | 5 | 4 | 0.40 | 1.360 | 0.350 | 288.57% |
| 2023-05-14 | 3 | 4 | 0.30 | 1.287 | 0.252 | 410.71% |
OCX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.67 | 0 | 1 | 2 | 0 | 0 | 3 |
The Trend in the Broker Recommendations
OCX's average broker recommendation rating worsened by 1.67 over the prior 35 months.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- OCX has a higher average analyst price target than 82.04% of all US stocks.
- OCX has a greater upside potential (average analyst target price relative to current price) than 2617.58% of all US stocks.
- ONCOCYTE CORP's variance in analysts' estimates is lower than -2332.24% of stocks in the small market cap category.
- In the context of Healthcare stocks, ONCOCYTE CORP's number of analysts covering the stock is higher than 695.5% of them.
In the Pharmaceutical Products industry, TRIB, ABIO, and TKNO are the three stocks most similar to ONCOCYTE CORP regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
What is the outlook for OCX? Use POWR Ratings for clearer insight into price direction.